Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,423.55
    +255.48 (+0.64%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,720.75
    +1,606.38 (+2.32%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,539.57
    +8.97 (+0.59%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Skyepharma estimates full-year revenue ahead of its expectations

(Reuters) - Skyepharma Plc (SKP.L) said it estimated full-year revenue to be ahead of its previous expectations as its licence partner, Mundipharma, had agreed to record the first sales milestone of its asthma therapy flutiform in 2015.

The pharmaceutical company said the milestone would be released as deferred income and it would not receive any cash from it as it would be used to meet a part of Mundipharma's right to recover previous development costs.

(Reporting by Esha Vaish in Bengaluru; Editing by Gopakumar Warrier)